Posted by Michael Wonder on 21 May 2024
Teva and Alvotech announce Simlandi (adalimumab-ryvk) injection now available in the US
20 May 2024 - Simlandi is the first interchangeable high concentration, citrate-free biosimilar to Humira.
Teva Pharmaceuticals and Alvotech today announced the availability of Simlandi (adalimumab-ryvk) injection in the US, as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis.
